Abstract:Tumors often display a high degree of intratumoral heterogeneity as manifested by dynamic changes in gene expression, protein expression, and on gross examination of histology, among many other features. Clinically, this underlying heterogeneity can drive tumor evolution and progression towards a more aggressive neoplastic state and a worse prognosis for patients; therefore, identifying the diverse composition of a tumor for early risk stratification is of critical importance. To elucidate intratumoral heterogeneity and intracellular hierarchy in a novel manner, we first conducted a low-cost quantitative proteomics analysis using MALDI-TOF mass spectrometry on over 1900 samples from different histological regions of individual tumors from 35 lung cancer patients, as well as from 3 mesenchymal stem cell samples. The histologies identified were acinar, basal cells, bronchial epithelium, lepidic, complex gland, micropapillary, near tumor normal, normal alveolar, papillary, papillary lepidic, papillary mucinous, and solid. Patient-specific information including survival status, sex, age, smoking status, SUV by FDG-PET scan, tumor size, EGFR, KRAS, and ERCC1 mutation status, among other variables was obtained. We then compared the proteomes derived from each tumor to the stem cell proteomes, and using computational strategies, mapped the distance of each histological sample from the mesenchymal stem cell state; using clustering techniques, we organized the major histological subtypes into a phylogenetic tree from stem cells to normal lung. We hypothesized that by applying and improving upon map of tumor evolution based on the distance of each individual histological sample from a stem cell state. Apart from liquid tumors, there have thus far been limited studies on the prognostic significance of different subclones in solid tumors, and therefore we treated each histological sample as a subclone within each patient. We also aimed to identify survival-associated subclones and prognostic molecular signatures across combinations of subclones. Identifying these subclones may provide insight into malignant micrometastases to other organs. Using co-expression network analysis, we further pinpointed distinctive significantly dysregulated co-regulatory protein networks within each histological subtype. Based on these networks, we sought to identify important hub proteins within each histology. Ultimately, using proteomic profiling in solid tumors can be a novel approach in functionally characterizing intratumoral heterogeneity, and may allow for a more robust analysis of the diverse molecular expression of single tumor samples. Our results may help inform the field of targeted broad-scale proteomics profiling for therapeutic use. Citation Format: Charlotte Lee, Hua-Jun Wu, Andre L. Moreira, Erin H. Seeley, Callee Walsh, Robert J. Downey, Franziska Michor. Proteomic profiling to elucidate intratumoral heterogeneity and cancer evolution in lung cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A21.

Heterogeneity of Lipidomic Profiles among Lung Cancer Subtypes of Patients

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

Clinical Lipidomics in Understanding of Lung Cancer: Opportunity and Challenge.

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

Trans‐omic profiling between clinical phenoms and lipidomes among patients with different subtypes of lung cancer

Integration of clinical phenoms and metabolomics facilitates precision medicine for lung cancer

Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data

Exploring lipidomic profiles and their correlation with hormone receptor and HER2 status in breast cancer

Molecular Classification of Genes Associated with Hypoxic Lipid Metabolism in Pancreatic Cancer

Metabolomic analysis of lung cancer patients with chronic obstructive pulmonary disease using gas chromatography-mass spectrometry

Characterizing microbiota and metabolomics analysis to identify candidate biomarkers in lung cancer

A Global View of Regulatory Networks in Lung Cancer: an approach to understand homogeneity and heterogeneity.

In-depth analysis of immune cell landscapes reveals differences between lung adenocarcinoma and lung squamous cell carcinoma

Immune and non-immune cell subtypes identify novel targets for prognostic and therapeutic strategy: A study based on intratumoral heterogenicity analysis of multicenter scRNA-seq datasets in lung adenocarcinoma

Identification of distinct tumor cell patterns with single-cell RNA sequencing integrating primary lung adenocarcinoma and brain metastasis tumor

Plasma Lipidomics Profiling to Identify the Biomarkers of Diagnosis and Radiotherapy Response for Advanced Non-Small-Cell Lung Cancer Patients

Integrative Proteomic Characterization of Human Lung Adenocarcinoma

Lipid Metabolism-Related Gene Markers Used for Prediction Prognosis, Immune Microenvironment, and Tumor Stage of Pancreatic Cancer

Multi-omics characterization and machine learning of lung adenocarcinoma molecular subtypes to guide precise chemotherapy and immunotherapy

Screening and Identification of Potential Novel Lipid Biomarkers for Non‐small Cell Lung Cancer Using Ultra‐high Performance Liquid Chromatography Tandem Mass Spectrometry

Abstract A21: Proteomic Profiling to Elucidate Intratumoral Heterogeneity and Cancer Evolution in Lung Cancer